Ignite Creation Date:
2025-12-24 @ 9:28 PM
Ignite Modification Date:
2025-12-31 @ 8:20 PM
Study NCT ID:
NCT05245032
Status:
COMPLETED
Last Update Posted:
2025-03-14
First Post:
2022-02-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Biologically Focused Therapy of Treatment-Refractory MDS Patients
Sponsor:
Stanford University
Organization:
Study Overview
Official Title:
Biologically Focused Therapy of Treatment Refractory MDS Patients
Status:
COMPLETED
Status Verified Date:
2025-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This non interventional study examines the feasibility of using patient specific therapeutic screening method, ex vivo to enhance current treatment recommendations in a clinically feasible time frame of 30 days.
Detailed Description:
This study utilizes the Notable Labs personalized testing service using an ex vivo assay, but does not involve actual treatment or treatment determinations. The results of these screenings will be made available to patients and their physicians for their use off study.
The primary objective of the study is:
• To determine the feasibility of selecting patient specific treatment regimens based on ex vivo within 30 days
The exploratory objectives of the study are:
• To identify biomarkers that explain ex vivo drug sensitivity results
The primary objective of the study is:
• To determine the feasibility of selecting patient specific treatment regimens based on ex vivo within 30 days
The exploratory objectives of the study are:
• To identify biomarkers that explain ex vivo drug sensitivity results
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: